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Non–High-Density Lipoprotein Cholesterol Versus
Apolipoprotein B in Cardiovascular Risk Stratification
Do the Math
Vimal Ramjee, MD,* Laurence S. Sperling, MD,† Terry A. Jacobson, MD‡
Atlanta, Georgia
With the emergence of new lipid risk markers and a growing cardiometabolic risk burden in the United States,
there is a need to better integrate residual risk into cardiovascular disease (CVD) risk stratification. In anticipa-
tion of the Adult Treatment Panel IV (ATP IV) guidelines from the National Cholesterol Education Program
(NCEP), there exists controversy regarding the comparative performance of the 2 foremost markers, apolipopro-
tein B (apoB) and non–high-density lipoprotein cholesterol (non–HDL-C), as they relate to the current standard of
risk assessment and treatment: low-density lipoprotein cholesterol (LDL-C). Although some emerging markers
may demonstrate better performance compared with LDL-C, certain fundamental characteristics intrinsic to a
beneficial biomarker must be met prior to routine use. Collectively, studies have found that non–HDL-C and apoB
perform better than LDL-C in CVD risk prediction, both on- and off-treatment, as well as in subclinical CVD risk
prediction. The performance of non–HDL-C compared with apoB, however, has been a point of ongoing debate.
Although both offer the practical benefits of accuracy independent of triglyceride level and prandial state, non–
HDL-C proves to be the better marker of choice at this time, given established cutpoints with safe and achiev-
able goals, no additional cost, and quick time to result with an easy mathematical calculation. The purpose of
this review is to assess the performance of these parameters in this context and to discuss the consider-
ations of implementation into clinical practice. (J Am Coll Cardiol 2011;58:457–63) © 2011 by the
American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.05.009Less is more.
—Ludwig Mies van der Rohe (1)
Current guidelines from the National Cholesterol Educa-
tion Program (NCEP) rely on low-density lipoprotein
cholesterol (LDL-C) as the primary therapeutic target in
the prevention of cardiovascular disease (CVD) (2). Al-
though LDL-C is well established as an important prog-
nostic marker of coronary heart disease (CHD), population
trends suggest the need for better risk stratification. Epide-
miological considerations include the recurrence of acute
coronary syndromes in up to one-half of patients with
“normal” cholesterol levels, and the occurrence of coronary
events despite the aggressive use of statins (3). Although
statin therapy provides a significant relative risk reduction of
30%, many CHD patients are still having events with
LDL-C at goal (2,4,5). In the United States, more than
50% of acute coronary syndromes are recurrent in nature
From the *J. Willis Hurst Internal Medicine Residency, Emory University School of
Medicine, Atlanta, Georgia; †Section of Preventive Cardiology, Emory University,
Atlanta, Georgia; and the ‡Department of Medicine, Office of Health Promotion,
Emory University, Atlanta, Georgia. The authors report that they have no relation-
ships to disclose.Manuscript received December 28, 2010; revised manuscript received April 28,
2011, accepted May 10, 2011.despite a 6-fold increase in the control of LDL-C among
hypercholesterolemic patients (3). Taken together, these
findings suggest opportunities for further risk reduction of
this population. Emerging research has identified potential
surrogate lipid markers for assessing cardiovascular risk,
including apolipoprotein B (apoB), small dense LDL, LDL
particle number, and non–high-density lipoprotein choles-
terol (non–HDL-C). The aim of this review is to compare
the current standard-of-care lipid marker—LDL-C—to the
2 foremost emerging markers in CVD risk stratification,
non–HDL-C and apoB.
See page 464
The Conventional Marker of Risk: LDL-C
A conventional lipid panel reports several parameters, in-
cluding total cholesterol (TC), LDL-C, high-density lipo-
protein cholesterol (HDL-C), and triglycerides (TG). Of
these, the NCEP (2) and the American Heart Association
(3) recommend using LDL-C as a primary target of therapy
in conjunction with assessing cardiovascular risk factors.
Guidelines over the past 3 decades have maintained that
LDL-C should be the main target of treatment based on
several large trials (6–9), with the corollary that intensifi-
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LDL-C in secondary prevention
patients is now warranted (10).
Although LDL-C is a well-
founded target, emerging find-
ings suggest that it has become a
suboptimal marker of risk for a
number of reasons (11,12). Pop-
ulation trends in the United
States by the National Health
and Nutrition Examination Sur-
vey (NHANES) and the Amer-
ican Heart Association report
that the prevalence of each indi-
vidual characteristic of the meta-
bolic syndrome has increased
over the past decade and is pro-
jected to continue increasing at a
rapid rate (Table 1) (3,13–15).
These characteristics lead to a
larger free fatty acid burden on
hepatocytes, as well as down-
regulation of lipoprotein lipase
(LPL) through relative insulin
inefficiency (16). Such changes
result in a preponderance of very
low-density lipoprotein choles-
terol (VLDL) and other lipopro-
teins, which are better accounted
for by non–HDL-C and apoB
compared with LDL-C. Importantly, the value routinely
reported as LDL-C by laboratories is calculated using the
Friedewald equation, which is known to lose accuracy with
elevated triglycerides or with an LDL-C 100 mg/dl
(17,18). Given the growing cardiometabolic burden in the
United States, targets of therapy other than LDL-C need to
be considered.
Emerging Markers of Risk: ApoB and Non–HDL-C
With the intent of assessing complete lipid atherogenic risk
burden—rather than a partial one, such as LDL-C—the ideal
parameter is one that accounts for all atherogenic cholesterol
particles, including LDL-C, Lp(a), intermediate-density lipo-
protein cholesterol, chylomicron remnants, and VLDL-C
(19,20). The dynamic flux of lipoproteins between subtypes
under direction of LPL and cholesterol ester transfer protein
(CETP) makes direct assessment of total atherogenic burden a
challenge, which is significantly improved by apoB and non–
HDL-C (19,21). Apolipoprotein B is able to directly measure
the aggregate number of all atherogenic lipoproteins because
each atherogenic particle contains 1 apoB100 molecule.
Non–HDL-C is an established secondary target of ther-
py per the NCEP ATP III guidelines that remains
nderutilized in the clinical setting (22). With conventional
Abbreviations
and Acronyms
AACC  American
Association of Clinical
Chemistry
ACC  American College of
Cardiology
ADA  American Diabetes
Association
apoB  apolipoprotein B
CHD  coronary heart
disease
CI  confidence interval
CVD  cardiovascular
disease
HDL-C  high-density
lipoprotein cholesterol
HR  hazard ratio
LDL-C  low-density
lipoprotein cholesterol
NCEP  National
Cholesterol Education
Program
NRI  net reclassification
index
TC  total cholesterol
TG  triglycerides
VLDL-C  very low-density
lipoprotein cholesterolnalysis, non–HDL-C is able to quantify total atherogenic
1urden by measuring the aggregate amount of “cholesterol”
n all contributive particles. Non–HDL-C is a quick and
imple calculation of TC minus HDL-C (TC  HDL-C),
nd can be obtained in the non-fasting state without
ffecting results.
oving beyond LDL-centric management. Although
DL-C has been the primary measure used to estimate
VD risk by guidelines for over 3 decades, there are now
any studies demonstrating consistent outperformance by
on–HDL-C (23–29). In the Lipid Research Clinics Pro-
ram Follow-Up study (11), 4,462 primary prevention
ndividuals (age: 40 to 64 years) were followed over an
verage of 19 years. In this study, Cui et al. (11) found that
on–HDL-C was a stronger predictor of all-cause mortal-
ty, as well as CVD mortality compared with LDL-C
chi-square for non–HDL-C: 24.3, and chi-square for
DL-C: 5.0). The BARI (Bypass Angioplasty Revascular-
zation Investigation) study (25) followed 1,514 secondary
revention patients with multivessel disease for 5 years and
ound that non–HDL-C was a significant, independent
redictor of nonfatal myocardial infarction (MI) (relative
isk [RR]: 1.049, p  0.05, per 10 mg/dl increase) with
ose-dependent effects on multivariate analysis. Further-
ore, LDL-C was not a significant predictor of either of
hese endpoints or all-cause mortality (25).
Although current recommendations are limited to ther-
peutic targeting of non–HDL-C in patients who have a
G level200 mg/dl (or2.26 mmol/l), non–HDL-C has
een proven to perform better than LDL-C at all TG levels.
n the SHEP (Systolic Hypertension in the Elderly Pro-
ram) (26), for example, 4,736 primary and secondary
revention patients (mean age 72 years) were assessed for
HD risk. In this study, non–HDL-C was found to be an
ndependent predictor of CHD regardless of TG level,
hereas LDL-C lost predictive value with TG 400 mg/dl
26). Similarly, in the EPIC-Norfolk study (30), non–
DL-C was the strongest predictor of future CHD (men
nd women, age 45 to 79 years) across all other lipid-
tratified levels, including patients with a TG 200 mg/dl.
he ERFC (Emerging Risk Factors Collaboration) (31)
United States: A Growing CardiometabolicPhenotypeTable 1 United States: A Growing CardiometabolicPhenotype
1994–2002 2003–2010  (%)
MetS 23.7% 34.0% 10.3
High TG 27.0% 33.0% 6.0
High TG and low HDL-C 2.1% 4.8% 2.7
Type II diabetes mellitus 7.9% 10.7% 2.8
Impaired fasting glucose 6.1% 25.9% 19.8
Obesity 19.8% 33.7% 13.9
Boldface values highlight the percent change in each individual characteristic of the metabolic
syndrome. Percentage prevalence of cardiometabolic profile characteristics in adults20 years of
ge in the United States. Individual characteristics include those of metabolic syndrome (MetS):
igh triglycerides (TG) (150 mg/dl), low high-density lipoprotein cholesterol (HDL-C) (40 mg/dl
n men, 50 mg/dl in women), impaired fasting glucose (fasting plasma glucose: 100 mg/dl to
225 mg/dl), type 2 diabetes mellitus, and obesity (body mass index 30 kg/m ). Table is based
on data from Lloyd-Jones et al. (3), Flegal et al. (13), Gardner et al. (14), and Mokdad et al. (15).
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July 26, 2011:457–63 Non-HDL Versus ApoB in Cardiovascular Risk Stratificationfound that TG levels were not independently associated
with CHD risk once adjusted for non–HDL-C in 302,430
individuals. These findings support the expanded use of
non–HDL-C as a primary therapeutic target. By using
non–HDL-C as a primary therapeutic target, management
of patients will become less fragmented through allowance
of single-parameter risk stratification independent of TG
level.
Non–HDL-C and the cardiometabolic profile. Approxi-
mately 34% of adults in the United States have the meta-
bolic syndrome with characteristically high TG, low
HDL-C, and LDL-C often within normal limits. Given
this predisposition, in the setting of an increasingly obese,
insulin-resistant, and diabetic population in the United
States (Table 1), LDL-C has become less of an important
marker of CVD risk (3). Pertaining to these epidemiologic
trends, a pooled post-hoc analysis of outcomes using data
from 4 large studies—FCS (Framingham Cohort Study),
FOS (Framingham Offspring Study), LRCF (Lipid Re-
search Clinics Prevalence Follow-Up) study, and the
MRFIT (Multiple Risk Factors Intervention Trials)—
demonstrated significantly higher values of non–HDL-C in
diabetic patients compared with nondiabetic patients (194.1
and 176.7 mg/dl, respectively, p  0.001), but nearly
identical LDL-C levels (148.6 and 148.0 mg/dl, respec-
tively, p  0.68) (11,32). These findings underscore the
limited ability of LDL-C to account for the well-established
cardiometabolic lipid burden in this population (11,32).
Non–HDL-C is a better therapeutic target than LDL-C
for several well-based reasons. In population studies, non–
HDL-C correlates better with the characteristics of the
metabolic syndrome (14,23,32). Non–HDL-C is twice as
good as LDL-C in predicting risk reduction, and has
demonstrated dose-dependent effects in predictive models
of CVD more consistently than LDL-C (20,23,27–29,32).
Cutpoints for non–HDL-C goals are based on well-
established goals for LDL-C used in the current NCEP
guidelines (Table 2).
Non–HDL-C or ApoB: the ongoing debate. There exists
continuing controversy as to the comparative performance
of non–HDL-C and apoB. Epidemiological studies and ran-
Current NCEP Guidelines for LDL-C and Non–HDL-CTable 2 Current NCEP Guidelines for LDL-C and Non–HDL-C
Risk Level
LDL-C Goal
(mg/dl)
Non–HDL-C Goal
(mg/dl)
Highest risk (CHD, CHD equivalent,
or 10-yr risk score 20%)
100 (70*) 130 (100*)
Moderately high risk (2 risk factors,
or 10-yr risk score  10%–20%)
130 (100*†) 160 (130†)
Moderate risk (2 risk factors,
or 10-yr risk score 10%)
 130  160
Low risk (2 risk factors,
or 10-yr risk score 10%)
 160  190
*Optional goal for very-high risk patients; †optional goal for higher-risk patients. Table is based on
data from NCEP Expert Panel (2).
apoB  apolipoprotein B; CHD  coronary heart disease; HDL-C  high-density lipoprotein1
cholesterol; LDL-C  low-density lipoprotein cholesterol; NCEP  National Cholesterol Education
Program.domized controlled trials, including AFCAPS/TexCAPS (Air
Force/Texas Coronary Atherosclerosis Prevention Study) (33),
AMORIS (Apolipoprotein Mortality Risk Study) (34), and
INTERHEART (35), have played an integral role in intro-
ducing apoB and apolipoprotein ratios as parameters that
may offer more than conventional lipid measures in CVD
risk prediction (36).
CVD risk prediction in epidemiological studies. The
AMORIS (34) study found that apoB was a more accurate
predictor of CVD risk compared with LDL-C among
175,553 healthy individuals (mean age 47 years) (RR for
MI: 1.33 and 1.53 in men and women, respectively) (36).
These findings, however, have questionable utility given
significant design limitations including lipid measurement
through nonconventional methodology and minimal adjust-
ment for confounding variables (34). The INTERHEART
study demonstrated a graded association of the apoB/
apoA-I ratio to risk of MI in 29,972 individuals. This study,
however, did not directly assess apoB compared with
LDL-C (35).
Multiple studies report that apoB has the strongest
association with CHD risk compared with conventional
measures (37–40). The Health Professionals Follow-Up
study (40), for instance, compared lipid measures in the
prediction of CHD among 18,225 men (age 40 to 75 years)
and found that although non–HDL-C outperformed
LDL-C in CHD risk prediction (non–HDL-C RR: 2.99,
ptrend  0.006; LDL-C RR: 0.86, ptrend  0.75), apoB
outperformed non–HDL-C (apoB RR: 3.99, ptrend  0.02;
non–HDL-C RR: 0.73, ptrend  0.76) in multivariate-
djusted models. The high age-adjusted Spearman correla-
ion coefficient between non–HDL-C and apoB (r  0.93,
 0.0001)—a common finding in several studies
27,41–43)—underscores the significant degree of colinear-
ty between these 2 parameters, which renders logistic
egression analyses less reliable (5). Furthermore, implicit to
he relationship of high correlation in the setting of mod-
rate concordance is the inability of apoB as an individual
easure to substitute for a conventional lipid parameter
uch as non–HDL-C, but rather to be used adjunctively
ith it (19,36,40).
In the Women’s Heart Study (27), 15,632 healthy
omen 45 years of age were followed prospectively over
0 years. Future major cardiovascular events were found to
e equally associated with apoB (hazard ratio [HR]: 2.50,
5% confidence interval [CI]: 1.68 to 3.72) and non–
DL-C (HR: 2.51, 95% CI: 1.69 to 3.72), both of which
erformed better than all other individual lipid and apoli-
oprotein parameters (27).
The most compelling and largest epidemiological study to
ate was completed by the Emerging Risk Factors Collab-
ration (31). In this analysis of 22 studies with 91,307
ndividuals, non–HDL-C and apoB were the most predic-
ive parameters in fully adjusted analyses (non–HDL-C
R: 1.59, 95% CI: 1.36 to 1.85; apoB HR: 1.58, 95% CI:
.39 to 1.79) (31). However, others have criticized the
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studies (34,35).
On-treatment CVD risk prediction. In AFCAPS/
TexCAPS, on-treatment apoB was a better predictor than
LDL-C for developing an acute coronary event in 6,605
primary prevention individuals (apoB, p 0.0001; LDL-C,
p  0.062) (33). This study, however, did not assess the
omparative performance of apoB and non–HDL-C in
VD risk prediction.
Recently, the TNT (Treating to New Targets) (29) and
DEAL (Incremental Decrease in Endpoints through Ag-
ressive Lipid Lowering) (28) trials prospectively assessed
ardiovascular outcomes in 18,018 secondary prevention
ndividuals (mean age: 61.3 years) randomized to low-
ersus high-dose statin therapy. In these predominantly
ormotriglyceridemic individuals, non–HDL-C better pre-
icted cardiovascular risk when prospectively compared with
DL-C (23,28,29).
A combined analysis of both trials assessed comparative
n-treatment performance of apoB, LDL-C, and non–
DL-C (23). In this analysis, non–HDL-C was found to
ave a higher association with future major cardiovascular
vents (HR: 1.31, 95% CI: 1.19 to 1.44, p  0.001)
ompared with LDL-C (HR: 0.90, 95% CI: 0.82 to 0.99,
 0.04), and was equally as associated (HR: 1.19, p 
.001) with future major cardiovascular events as apoB
HR: 1.19, p  0.001) (23,28,29). Direct pair-wise com-
arison of apoB and non–HDL-C, however, showed that
on–HDL-C was more strongly associated with major
ardiovascular events (HR: 1.14, p  0.06) than apoB (HR:
.05, p  0.47) (23).
isk reclassification. With clinical prognostic models, the
mpact that a given marker may have on outcomes can be
ccurately assessed by calculating the percentage of reclas-
ified individuals expressed as the net reclassification index
NRI) (44). Although the Framingham Study found that
poB (men, RR: 1.37, p  0.001; women, RR: 1.38, p 
0.001) was better than non–HDL-C (men, RR: 1.22, p 
0.005; women, RR: 1.28, p  0.01) in CHD risk predic-
tion, reclassification of individuals with the respective ratio
parameters in sex-pooled analyses was minimally affected
(0.1%) and not statistically significant (41).
These findings were further supported in the Women’s
Health Study (45), in which apoB only reclassified 2.6% of
all individuals when compared with a conventional lipid
Discrepant ApoB CutpointsTable 3 Discrepant ApoB Cutpoints
NCEP LDL-C Go
Highest-risk patients, mg/dl 70
High-risk patients, mg/dl 100
Moderate-risk patients, mg/dl 130
Table is based on data from Brunzell et al. (17), Contois et al. (36), a
AACC  American Association of Clinical Chemistry; ADA/ACC  Amer
Canadian Cardiovascular Society; NS  not specified; other abbreviations asratio reference model (TC/HDL-C). Notably, the reclassi-
fication percentage reported included both correctly and
incorrectly reclassified individuals, thereby making the ex-
ceptionally low NRI even lower for correctly reclassified
individuals. These findings indicate the negligible benefit of
using apoB or the apoB/apoA-I ratio in cardiovascular risk
prediction when considering their effect on outcomes from
a practical standpoint.
Subclinical atherosclerosis: non-HDL or apoB? Non–
HDL-C and apoB as predictors of subclinical atherosclero-
sis have been assessed in multiple studies with conflicting
findings (42,46,47). Although developed imaging modali-
ties allow for indirect assessment of subclinical vascular
disease, postmortem examination from the PDAY (Patho-
logical Determinants of Atherosclerosis in Youth) study
(48,49) may offer a more definitive assessment (49). In this
study, individuals from 15 to 34 years of age who died of
external causes were autopsied. Extent of fatty streaks and
raised lesions in the thoracic aorta, abdominal aorta, and
right coronary artery for each individual were graded by
independent pathologists (48). A multiple linear regression
analysis was completed assessing the association of lipid and
apolipoprotein parameters to vascular lesion grading. Non–
HDL-C was significantly associated with fatty streaks in all
3 sites assessed (p  0.0001), as well as with raised lesions
n the abdominal (p  0.0465) and thoracic aorta (p 
.0103). ApoB was not significantly associated with any
aised lesions, and was at best, 16 times less associated with
atty streaks compared with non–HDL-C (48,49). Collec-
ively, these findings favor non–HDL-C over apoB as a
etter measure of subclinical atherosclerosis and global
rognostic risk.
reatment targets. Although treatment goals for LDL-C
nd non–HDL-C are delineated in the NCEP guidelines,
poB goals to date have been controversial and unclear
17,36). While treatment targets for apoB—like those for
DL-C and non–HDL-C—can be derived from certain
opulation studies, there exists a large discrepancy in the
roposed apoB cutpoints by different national organizations
Table 3) (17,36,50).
The American Diabetes Association (ADA)/American
ollege of Cardiology (ACC) (15) position statement
ecommends an apoB goal of 80 mg/dl in highest-risk
atients and 90 mg/dl in high-risk patients. In contrast,
he American Association of Clinical Chemistry (AACC)
ApoB Goals
ADA/ACC AACC CCS
80 NS NS
90 80 80
NS 100 80
st et al. (50).als
nd Gene
ican Diabetes Association/American College of Cardiology; CCS 
in Table 2.
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July 26, 2011:457–63 Non-HDL Versus ApoB in Cardiovascular Risk Stratification(36) recommends an apoB goal of 80 mg/dl in high-risk
patients. The Canadian Cardiovascular Society is in dis-
agreement with the ADA/ACC and the AACC, as they
recommend an apoB 80 mg/dl as the primary therapeutic
target in high- and moderate-risk patients (50).
The NCEP LDL-C goals of 70 mg/dl, 100 mg/dl, and
130 mg/dl correspond to different apoB cutpoints depend-
ing on whether Framingham (55 mg/dl, 80 mg/dl, and 100
mg/dl, respectively) or NHANES III (70 mg/dl, 90 mg/dl,
and 110 mg/dl, respectively) population percentiles are
applied (51). These discrepant percentile equivalents may
contribute to the varying cutpoints proposed by different
national organizations (Table 3) (17,36,50). Additionally,
percentiles for cutpoints based on certain populations—
particularly with Framingham—are somewhat outdated in
corresponding lipid parameters, given interval gain over the
past 2 decades in characteristics of the metabolic syndrome
(Table 1) (3,13,52). With apoB cutpoints arbitrarily set on
ifferent population percentiles and only intermittently on
DL-C goals (17,36,50,51), current proposed therapeutic
argets need to be re-evaluated.
Although studies with lower goal attainment rates of
poB compared with non–HDL-C suggest that non–
DL-C is a less useful target, it is important not to equate
ore challenging goal attainment with better outcomes.
tein et al. (19) found that although a majority of patients
chieved LDL-C or non–HDL-C goal (60%), only a
inority achieved an apoB 90 mg/dl (30%) in 22,000
pecimens. The poor apoB goal attainment rate across all
roups studied, normotriglyceridemic and hypertriglyceri-
emic individuals, and at all risk levels, highlights the
ikelihood of miscalibrated cutpoints for apoB, as well as the
imited availability of efficacious interventions for apoB
oal-directed therapy. With statins as the current mainstay
f treatment, 1 study assessed the differential effects of the
ost commonly used statins at a full spectrum of approved
oses in lowering major lipid parameters for 17,035 pre-
ominantly high-risk individuals (53). Despite the wide
rray of interventions applied, the substantially higher pop-
lation percentile that apoB was lowered to (55th, p 
.001) compared with non–HDL-C (29th, p  0.001) or
DL-C (22nd, p  0.001) suggests a need for better
poB-directed medications (Table 3). Furthermore, the
National Reference Laboratory Indices ofApoB Versus Non–HDL-C Cost a Time to RepoTable 4 National Reference Laboratory IndicApoB Versus Non–HDL-C Cost and T
National
Reference Lab ApoB Methodology Unit Cos
ARUP Lab Immunonephelometry 50.0
Mayo Medical Lab Turbidimetry 108.3
Mean values 79.
Unit cost , % 1
Time-to-report , % 1
Boldface values highlight themean values relevant to cost and time to
Laboratories: ARUP and Mayo Medical Laboratories.
Abbreviations as in Table 2.nability to achieve a mean apoB level below the 55th
ercentile in the setting of recommended goals for apoB
anging from the 10th to 50th percentile by national
rganizations (17,36,50,51,53), underscores a concerning
reatment–goal gap that necessitates identification of effec-
ive treatment strategies and appropriate cutpoints for apoB
rior to implementation. To reach the current proposed
poB goals, therapies in addition to high-dose statins would
nevitably be needed, yet the evidence base for this approach
s still incomplete.
ractical barriers to ApoB implementation. There are
ignificant barriers to making apoB a primary therapeutic
arget in the management of individuals at risk for CVD.
riefly considering the immediate test costs puts into
erspective the financial concern of such a paradigm shift in
ipid management. Current mean values from national
eference laboratories indicate a unit cost of checking 1
outine apoB level is $79.15, whereas the unit cost of
hecking an entire conventional lipid panel including TC,
G, LDL-C, HDL-C, and non–HDL-C is only $59.20
Table 4). Since apoB cannot act as a stand-alone target, the
rojected cost of this test is one that becomes compounded.
Although apoB testing methods have been standardized
o a greater degree over the past several years, there still
emains a significant lag time in test result reporting. The
ean time to report for national reference labs for apoB is
n average up to 4 times longer than that of non–HDL-C
Table 4). The discrepancy in test turnaround time despite
airly equivalent run-time is due to lack of routine in-house
poB testing in most U.S. hospitals and clinics (Table 4).
urthermore, introducing a new conceptual framework of
polipoproteins will likely require a long timeframe for
hysician’s acceptance, given that it took several decades for
DL-C to be routinely incorporated into clinical practice.
n contrast, non–HDL-C exists within the current concep-
ual framework of lipids and enables physicians to assess
atients at the same time as that of a conventional lipid
anel. This allows for a patient–physician interaction that
ay enable faster initiation of lipid-lowering therapies, a
reater number of effective interventions, better targeting
ith goal-directed therapy, and less likelihood of patients
eing lost to follow-up.
f
to Report
ApoB Non–HDL-C
Time to Report Unit Cost ($) Time to Report
1–4 days 30.00 1 day
1–4 days 88.40 1 day
1–4 days 59.20 <1 day
% with apoB
00% for apoB
or eachmarker. Table is based on 2010 data from National Referencertes o
ime
t ($)
0
0
15
33.7
up to 3
report f
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Both apoB and non–HDL-C are valuable parameters avail-
able to physicians for CVD risk stratification, with benefits
beyond that of LDL-C (Table 5). Although available
evidence suggests slightly better performance of apoB when
compared with non–HDL-C, significant practical limita-
tions of such a paradigm shift make apoB more of an
“additional” lipid test rather than an “advanced” lipid test.
Notable limitations of apoB include: 1) controversial find-
ings of better performance compared with non–HDL-C;
2) arbitrary treatment cutpoints, with ongoing disagreement
between national organizations; 3) insignificant population
benefit by NRIs; 4) potential increases in estimated direct
healthcare costs; 5) lag time in test-result reporting up to 4
times that of conventional parameters, with likely delays in
appropriate intervention; 6) lag time of conceptual under-
standing by the majority of practicing physicians; and
7) poor goal attainment rates on standard therapies, includ-
ing high-dose statins, with limited evidence for other
available interventions and therapeutic effects. Although
apoB looks very promising and may be of benefit in select
patients, more definitive evidence is needed on establishing
appropriate cutpoints and further delineating its benefits
prior to implementation.
Non–HDL-C, in contrast, demonstrates competitive
performance compared with apoB and offers several benefits
that apoB does not, including: 1) established cutpoints
based on LDL-C levels, which remain valid and indepen-
dent of increasingly discrepant population percentiles; 2) no
additional cost; 3) quick calculation of TC minus HDL-C;
4) well-documented intervention effects; and 5) existence
Comparative Performance of Emerging CVDRisk Markers: LDL-C, Non–HDL-C, and ApoBTable 5 Comparative Performance of Emerging CVDRisk Markers: LDL-C, Non–HDL-C, and ApoB
LDL-C Non–HDL-C ApoB
Performance
Relevance to emerging population X X
Assesses residual cardiometabolic risk X X
Off-treatment CVD risk prediction X XX XX
On-treatment CVD risk prediction XX XX
Subclinical CVD prediction XX X
Treatment reduces risk X XX XX
Additional risk reclassification X X
Ease of use
Independent of prandial state X X
Independent of triglyceride level X X
Familiar conceptual framework X X
Well-defined treatment targets X X
Well-defined intervention effects X X
Can safely meet recommended goals X X
Practical limitations
Routine in-hospital testing X X
Additional direct cost XX
Delayed time-to-result XX
CVD  cardiovascular disease; other abbreviations as in Table 2.within our current “cholesterol-oriented” conceptual frame-work, lending itself to minimal physician–education lag
time, and easy transition with implementation. These ben-
efits may lead to a cost savings with use of non–HDL-C as
a primary target by improving overall management of CVD
risk, and minimizing immediate test repetition by physi-
cians for confounded specimen samples. Although both
non–HDL-C and apoB perform better than LDL-C, non–
HDL-C is currently a more realistic primary target of
therapy, given its ease of use and implementation.
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